AI in healthcare surge could reduce face time with doctors, nurses

The boom in the emergence of AI and other innovative technologies in the healthcare space comes with a new risk: the expense of human contact.

That future, as outlined by NPR, sees patients receiving eye exams from software, while clinicians interpret data and healthcare navigators help patients move through the healthcare system. Yet as healthcare services can increasingly be conducted by machines, from diagnostics to health predictions and more, patients still need a human element in the process.

As the proliferation of AI in the healthcare space charges onward, nurses and doctors shouldn’t become “adjuncts to machines.” Instead, the machines should give healthcare professionals more time to spend with patients and potentially tackle the most challenging tasks.

"Medicine is a combination of art and science," which will be augmented by AI, Russ Altman, MD, PhD, professor of bioengineering and genetics at Stanford, told NPR. "But the act of laying your hands on a patient, showing that you really care about what is there, what their problem is [and] assuring them that you're going to be with them through an odyssey—that might take a while. That is very difficult to imagine being replaced by computers."

See the full article here.  

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.